Reagenti e strumenti per immunologia, biologia cellulare e biologia molecolare
 
> Ruxolitinib (S enantiomer) [941685-37-6]

Ruxolitinib (S enantiomer) [941685-37-6]

Stampa Stampa
Entra

Cat# HY-50856A-10mg

Size : 10mg

Marca : MedChemExpress

Richiedere ulteriori informazioni

Contatta il distributore locale :


Telefono : +1 850 650 7790

Ruxolitinib (S enantiomer) (S-Ruxolitinib) is the S-enantiomer of Ruxolitinib (HY-50856). Ruxolitinib (S enantiomer) is an orally active, potent JAK inhibitor.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Ruxolitinib (S enantiomer) Chemical Structure

Ruxolitinib (S enantiomer) Chemical Structure

CAS No. : 941685-37-6

This product is a controlled substance and not for sale in your territory.

Based on 4 publication(s) in Google Scholar

Other Forms of Ruxolitinib (S enantiomer):

  • Ruxolitinib In-stock
  • Ruxolitinib phosphate In-stock
  • Ruxolitinib sulfate Obtenir un devis
  • (Rac)-Ruxolitinib-d9 Obtenir un devis

Voir tous les produits spécifiques à Isoform JAK:

Voir toutes les isoformes
JAK1 JAK2 JAK3 Tyk2 JAK
Description

Ruxolitinib (S enantiomer) (S-Ruxolitinib) is the S-enantiomer of Ruxolitinib (HY-50856). Ruxolitinib (S enantiomer) is an orally active, potent JAK inhibitor[1][2].

IC50 & Target

JAK

 

In Vitro

Ruxolitinib (S enantiomer) (S-Ruxolitinib; 10 μM; 12 hours) suppresses IFNβ-induced expression of ISG, IFIT, and IFITM[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ruxolitinib (S enantiomer) Related Antibodies

RT-PCR[1]

Cell Line: Human small airway epithelial cells (SAECs)
Concentration: 10 μM
Incubation Time: 12 hours
Result: Suppressed IFNβ-induced expression of ISG, IFIT, and IFITM.
In Vivo

Ruxolitinib (S enantiomer) (S-Ruxolitinib; 30 mg/kg; Oral gavage; twice per day separated 10-12 h for 8 weeks) reduces haematopoietic cell expansion in MPN[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female wild-type C57BL/6J or Nes-gfp27 mice with myeloproliferative neoplasms (MPNs) in peripheral blood[2]
Dosage: 30 mg/kg (in 0.5% hydroxypropylmethylcellulose after solubilisation in DMSO)
Administration: Oral gavage; twice per day separated 10-12 h for 8 weeks
Result: Reduced haematopoietic cell expansion in MPN but it did not rescue bone marrow (BM) mesenchymal stem cells (MSCs).
Masse moléculaire

306.37

Formule

C17H18N6
CAS No.

941685-37-6
Appearance

Solid

Color

White to off-white

SMILES

N#CC[C@@H](C1CCCC1)N2N=CC(C3=NC=NC4=C3C=CN4)=C2
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvant et solubilité
In Vitro: 

DMSO : ≥ 100 mg/mL (326.40 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

1M HCl : 50 mg/mL (163.20 mM; ultrasonic and adjust pH to 1 with HCl)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.2640 mL 16.3201 mL 32.6403 mL
5 mM 0.6528 mL 3.2640 mL 6.5281 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Calculateur de molarité

  • Calculateur de dilution

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (8.16 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (8.16 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation

Purity: 99.94%

COA (252 KB) HNMR (259 KB) LCMS (93 KB)

Instruction de manipulation (2659 KB)
Références

  • [1]. Hye Kyung Lee, et al. JAK inhibitors dampen activation of interferon-stimulated transcription of ACE2 isoforms in human airway epithelial cells. Commun Biol. 2021 Jun 2;4(1):654.  [Content Brief]

    [2]. Lorena Arranz, et al. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature. 2014 Aug 7;512(7512):78-81.  [Content Brief]

  • [1]. Hye Kyung Lee, et al. JAK inhibitors dampen activation of interferon-stimulated transcription of ACE2 isoforms in human airway epithelial cells. Commun Biol. 2021 Jun 2;4(1):654.

    [2]. Lorena Arranz, et al. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature. 2014 Aug 7;512(7512):78-81.

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
1M HCl / DMSO 1 mM 3.2640 mL 16.3201 mL 32.6403 mL 81.6007 mL
5 mM 0.6528 mL 3.2640 mL 6.5281 mL 16.3201 mL
10 mM 0.3264 mL 1.6320 mL 3.2640 mL 8.1601 mL
15 mM 0.2176 mL 1.0880 mL 2.1760 mL 5.4400 mL
20 mM 0.1632 mL 0.8160 mL 1.6320 mL 4.0800 mL
25 mM 0.1306 mL 0.6528 mL 1.3056 mL 3.2640 mL
30 mM 0.1088 mL 0.5440 mL 1.0880 mL 2.7200 mL
40 mM 0.0816 mL 0.4080 mL 0.8160 mL 2.0400 mL
50 mM 0.0653 mL 0.3264 mL 0.6528 mL 1.6320 mL
60 mM 0.0544 mL 0.2720 mL 0.5440 mL 1.3600 mL
80 mM 0.0408 mL 0.2040 mL 0.4080 mL 1.0200 mL
100 mM 0.0326 mL 0.1632 mL 0.3264 mL 0.8160 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Ruxolitinib (S enantiomer) Related Classifications

  • Epigenetics Stem Cell/Wnt Protein Tyrosine Kinase/RTK JAK/STAT Signaling
  • JAK
Help & FAQs

Keywords:

Ruxolitinib (S enantiomer)941685-37-6S-Ruxolitinib S-INCB18424JAKJanus kinaseOrallyISGIFITIFITMMPNInhibitorinhibitorinhibit